

## MiR-101-3p in HCC

**Table S1.** Meta-analysis of miR-101 (including precursor and mature miR-101) expression and clinicopathological parameters of HCC

Clinicopathological parameters	Number of studies	OR (95% CI)	P	Heterogeneity		
				$\chi^2$	$I^2$ (%)	P
Age	6	0.74 (0.52-1.06)	0.100	1.00	0.0	0.963
Gender	6	0.82 (0.56-1.19)	0.296	2.25	0.0	0.814
Tumor size	5	1.36 (0.39-4.73)	0.625	13.28	69.9	0.010
Grade	5	0.33 (0.09-1.20)	0.093	18.34	78.2	0.001
TNM stage	5	0.25 (0.10-0.62)	0.003	17.85	77.6	0.001
AFP	5	0.63 (0.41-0.98)	0.038	2.04	0.0	0.729
HBsAg	3	0.67 (0.04-11.25)	0.780	10.78	81.4	0.005
HBV-DNA	3	1.93 (0.06-59.41)	0.706	16.62	88.0	<0.001
Cirrhosis	6	0.77 (0.51-1.18)	0.235	0.78	0.0	0.978